in Health care
Novartis gets CDSCO panel nod for Phase III CT of anticancer drug Ianalumab
New Delhi: In a significant development, pharmaceutical major Novartis has got the go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the Phase III clinical trial of anticancer drug Ianalumab (VAY736). However, this approval is subject to the condition that the applicant submit safety data on […] More
